Immature Acta2<sup>R179C/+</sup> smooth muscle cells cause moyamoya-like cerebrovascular lesions in mice prevented by boosting OXPHOS.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40603847.
- Also identified by DOI 10.1038/s41467-025-61042-3 and PMC identifier 12223207.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
ACTA2 pathogenic variants altering arginine 179 cause childhood-onset strokes due to moyamoya disease (MMD)-like occlusions of the distal internal carotid arteries, but the mechanisms of pathogenesis are unknown and no preventive treatments exist. Here we show that Acta2<sup>R179C/+</sup> smooth muscle cells (SMCs) fail to fully differentiate and maintain stem cell-like features, including increased migration and glycolytic flux compared to wildtype (WT) SMCs. Increasing mitochondrial respiration with nicotinamide riboside (NR) drives differentiation and decreases migration of Acta2<sup>R179C/+</sup> SMCs. Carotid artery injury of Acta2<sup>SMC-R179C/+</sup> mice leads to premature death, intraluminal SMC accumulation leading to MMD-like occlusive lesions, neurologic symptoms, and neuron loss, whereas injured WT mice have none of these phenotypes, and all are prevented by NR treatment in the Acta2<sup>SMC-R179C/+</sup> mice. These data show that driving differentiation and quiescence of Acta2<sup>R179C/+</sup> SMCs by altering cellular metabolism attenuates MMD-like disease in the Acta2<sup>SMC-R179C/+</sup> mice, highlighting a role of immature and highly migratory SMCs in the pathogenesis of MMD.
Medical subject headings
- Myocytes, Smooth Muscle
- Moyamoya Disease
- Actins
- Oxidative Phosphorylation